Differential effect on bone lesions of targeting integrins: Randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer

Clinical Cancer Research

Volumn 22, Issue 13, 2016, Pages 3192-3200

  Hussain, Maha ^a   Le Moulec, Sylvestre ^b   Gimmi, Claude ^c   Bruns, Rolf ^c   Straub, Josef ^c   Miller, Kurt ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b University of Paris Descartes   (France)

^c MERCK KGAA   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABITUZUMAB; ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; CD51 ANTIGEN; PLACEBO; GONADORELIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ARTICLE; BACKACHE; BONE LESION; BONE PAIN; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPERPHOSPHATASEMIA; IC95; IC99; INCIDENCE; INHIBITORY CONCENTRATION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; URINE RETENTION; AGONISTS; ANTAGONISTS AND INHIBITORS; BONE TUMOR; CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SECONDARY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOGLOBULIN G; INTEGRIN ALPHAV; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84977085543     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2512     Document Type: Article

References (42)

1. National Institute of Health and Clinical Excellence. Prostate cancer: diagnosis and treatment; 2014. Guideline CG175. London, United Kingdom. Available at: http://www.nice.org.uk/guidance/cg175/chapter/1-recommendations.
2. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596-605.
3. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014;32:3436-48.
4. Cathomas R, Bajory Z, Bouzid M, El Ghoneimy A, Gillessen S, Goncalves F, et al. Management of bone metastases in patients with castration-resistant prostate cancer. Urol Int 2014;92:377-86.
5. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol 2010;17Suppl 2:S72-S79.
6. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84.
7. National Institutes of Health. FDA approval for abiraterone acetate; 2013[cited 2015 Jun 5]. Available from: http://www.cancer.gov/about-cancer/treatment/drugs/fda-abirateroneacetate
8. US Food and Drug Administration. Enzalutamide (XTANDI Capsules). 2012. [cited 2015 June 5]. Available from: http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm317997.htm
9. European Medicines Agency. Assessment report: Zytiga (abiraterone). 2011. (EMA/CHMP/542871/2011). London, United Kingdom. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/002321/WC500112860.pdf. Accessed February 17, 2016.
10. European Medicines Agency. EPAR summary for the public: Xtandi (ezalutamide). 2014. (EMA/702100/2014, EMEA/H/C/002639). London, United Kingdom. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/002639/WC500144999.pdf. Accessed February 17, 2016.
11. Todenhöfer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol 2015;2015:838202.
12. De Franceschi N, Hamidi H, Alanko J, Sahgal P, Ivaska J. Integrin traffic - the update. J Cell Sci 2015;128:839-52.
13. Ganguly SS, Li X, Miranti CK. The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol 2014;4:364.
14. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer 2008;15:657-64.
15. Altieri DC, Languino LR, Lian JB, Stein JL, Leav I, van Wijnen AJ, et al. Prostate cancer regulatory networks. J Cell Biochem 2009;107:845-52.
16. Weis SM, Cheresh DA. αV integrins in angiogenesis and cancer. Cold Spring Harb Perspect Med 2011;1:a006478.
17. Heß K, Böger C, Behrens HM, Röcken C. Correlation between the expression of integrins in prostate cancer and clinical outcome in 1284 patients. Ann Diagn Pathol 2014;18:343-50.
18. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, et al. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 2009;69:1383-91.
19. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005;12:634-43.
20. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007;26:6238-43.
21. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M. Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003;20:413-20.
22. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci 2012;33:405-12.
23. Uhl W, Zühlsdorf M, Koernicke T, Forssmann U, Kovar A. Safety, tolerability, and pharmacokinetics of the novel av-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest New Drugs 2014;32:347-54.
24. Wirth M, Heidenreich A, Gschwend JE, Gil T, Zastrow S, Laniado M, et al. A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting av integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. Eur Urol 2014;65:897-904.
25. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
26. Goodman SL, Grote HJ, Wilm C. Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffinsamples of human tumors. Biol Open 2012;1:329-40.
27. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
28. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003;20:203-13.
29. Akalu A, Cretu A, Brooks PC. Targeting integrins for the control of tumour angiogenesis. Expert Opin Investig Drugs 2005;14:1475-86.
30. Munshi HG, Stack MS. Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev 2006;25:45-56.
31. Fornaro M, Manes T, Languino LR. Integrins and prostate cancer metastases. Cancer Metastasis Rev 2001;20:321-31.
32. Demetriou MC, Cress AE. Integrin clipping: a novel adhesion switch? J Cell Biochem 2004;91:26-35.
33. Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 2011;48:54-65.
34. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718-29.
35. Bennett JH, Moffatt S, Horton M. Cell adhesion molecules in human osteoblasts: structure and function. Histol Histopathol 2001;16: 603-11.
36. Alva A, Slovin S, Daignault S, Carducci M, Dipaola R, Pienta K, et al. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with nonmetastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 2012;30:749-57.
37. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs 2011;29:1432-40.
38. Chu FM, Picus J, Fracasso PM, Dreicer R, Lang Z, Foster B. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human alpha(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs 2011;29:674-9.
39. Heidenreich A, Rawal SK, Szkarlat K, Bogdanova N, Dirix L, Stenzl A, et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human alphanu integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann Oncol 2013;24:329-36.
40. Rosenthal MA, Davidson P, Rolland F, Campone M, Xue L, Han TH, et al. Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac J Clin Oncol 2010;6:42-8.
41. Suzuki K, Takeyama S, Sakai Y, Yamada S, Shinoda H. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci 2006;100:189-94.
42. Green JR. Bisphosphonates: preclinical review. Oncologist 2004;9Suppl 4:3-13.